Regulatory Strength Leverage Epicur Pharma's status as a 503B Outsourcing Facility under FDA oversight to position as a compliant manufacturing partner for sterile injectables and eye/animal health products, highlighting reliability for high-volume production and regulatory alignment.

Expanded Portfolio Target potential co-development or distribution deals around their established products (Tacrolimus Eyedrops, Buprenorphine Injection, Gabapentin tablets) and their growing animal health portfolio to broaden product offerings for contract manufacturing or private-label opportunities.

Strategic Partnerships Capitalize on the recent partnership with Bova Specials UK Limited to pursue additional cross-border collaborations, especially for equine health solutions and injectable formulations, tapping into veterinary and human-health channels.

Scale Opportunity With revenue in the $50M–$100M range and a mid-size employee base, propose scalable outsourcing engagements, feasibility studies for line extensions, and capacity planning to meet mid-market demand in sterile injectables and oral medications.

Tech & Compliance Highlight their tech stack and online presence as a foundation for streamlined client onboarding, quality/documentation workflows, and secure, compliant data exchange with customers seeking modern outsourcing partners.